SCCA、miR-501在宫颈癌患者血清中的表达水平及临床意义

Analysis of Serum SCCA and MiR-501 in Clinical Diagnosis and Prognostic Value of Cervical Cancer

[目的]探讨鳞状细胞癌抗原(squamous cell carcinoma antigen,SCCA)、miR-501在宫颈癌患者血清中的表达水平及其临床意义。[方法]选取2018年1月至2020年6月本院肿瘤科诊治的宫颈癌患者60例(观察组),另外选取同期在本院的健康体检者60例作为对照组。检测并对比两组血清SCCA、miR-501水平;同时比较不同疾病分期、淋巴结转移情况、病理分化及组织病理分型的宫颈癌患者血清SCCA、miR-501水平,ROC曲线分析血清SC-CA.miR-501水平对宫颈癌的诊断效能,统计不同SCCA、miR-501水平的宫颈癌患者总生存期(overall survival,OS)。[结果]观察组患者血清SCCA、miR-501水平均明显高于对照组(P<0.05)。宫颈癌患者血清SCCA、miR-501水平随疾病分期增加而增加,血清SCCA、miR-501水平随病理分化下降而增加,组间比较差异有统计学意义(P<0.05);有淋巴结转移者血清SCCA、miR-501水平明显高于无淋巴结转移者,鳞癌患者血清SCCA明显高于腺癌患者,其差异均具有统计学意义(P<0.05),鳞癌患者血清miR-501水平与腺癌患者比较差异无统计学意义(P>0.05)。血清SCCA、miR-501水平诊断宫颈癌的受试者工作特征(receiver operating characteristic curve,ROC)曲线下面积分别为0.869(95%CI:0.809~0.929)、0.911(95%CI:0.861~0.961),血清SCCA、miR-501诊断宫颈癌的最佳截断点分别为15.2 ng/mL和0.73。SCCA≤15.2 ng/mL患者的OS明显长于SCCA>15.2 ng/mL患者(P<0.05);miR-501≤0.73患者明显OS明显长于miR-501>0.73患者(P<0.05)。[结论]血清SCCA、miR-501水平可用于临床辅助诊断宫颈癌,预测宫颈癌的恶性程度、组织病理分型及患者预后。

[Objective]To study the value of serum SCCA and miR-501 in the clinical diagnosis and prognosis of patients with cervical cancer.[Methods]Sixty patients with cervical cancer admitted to the Oncology Department in our hospital from January 2018 to June 2020 were selected as the research objects and served as the observation group.A total of 60 healthy physical examination volunteers in the same period were selected as the control group.The serum SCCA and miR-501 levels of the two groups were compared.At the same time,the observation group's disease stage,lymph node metastasis,pathological differentiation and histopathological classification were counted,and the relationship of serum SC-CA and miR-501 levels with the patient's disease characteristics was analyzed.[Results]The serum SCCA and miR 501 levels of the observation group were significantly higher than those of the control group(P<<0.05).Serum SCCA and miR-501 were the best for diagnosis of cervical cancer The cut-off points are 15.2 ng/ml and 0.73,respectively.Serum SCCA and miR-501 levels increased with the increase of cervical cancer stage.The difference between stage Ⅰ,stage Ⅱ and stage Ⅱ was statistically significant(P<0.05),and the difference between stage Ⅱ and stage IV was not statistically significant(P>0.05).Serum SCCA and miR 501 levels increased with the decrease of cervical cancer pathological differentiation,and those with lymph node metastasis were significantly higher than those without lymph node metastasis,with statistically significant difference(P<0.05).The serum SCCA of patients with squamous cell carcinoma was significantly higher than that of patients with adenocarcinoma,and the difference was statistically significant(P<0.05).The level of serum miR-501 in patients with squamous cell carcinoma was significantly higher than that of adenocarcinoma.The difference between patients was not statistically significant(P>0.05).The area under the ROC curve for the diagnosis of cervical cancer by serum SCCA and miR-501 levels were 0.869(95%CI:0.809~0.929)and 0.911(95%CI:0.861~0.961),respectively.The best cut-off points of serum SCCA and miR-501 for diagnosis of cervical cancer were 15.2 ng/mL and 0.73,respectively.The OS of SCCA≤15.2 ng/ml was significantly longer than that of SCCA>15.2 ng/ml(P<0.05),and the OS of miR-501≤0.73 was significantly longer than that of miR-501>>0.73(P<0.05).[Conclusion]Serum SCCA and miR-501 levels can be used to assist clinical diagnosis of cervical cancer,predict the malignant degree of cervical cancer,histopathological classification and patient prognosis.